In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AITHORITY
AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced the launch of its first 2023 global call for applications to identify technological and biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
Visit: AION Labs launches second startup focused on AI-enabled antibody design
AION Labs launches second startup focused on AI-enabled antibody design
MobiHealthNews
DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.
Visit: AION Labs Launches AI Startup for De Novo Antibody Design
AION Labs Launches AI Startup for De Novo Antibody Design
PR Newswire
DenovAI is the second company to be formed by Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X.
Visit: Israel lab backed by pharma giants mints startup for computer-designed antibodies
Israel lab backed by pharma giants mints startup for computer-designed antibodies
Times of Israel
AION Labs, a consortium formed by Pfizer, Merck, AstraZeneca, Teva and others, sets up company to build a computational platform to design live-saving antibodies from scratch
Visit: New Israeli company aims to design life-saving proteins from scratch
New Israeli company aims to design life-saving proteins from scratch
The Jerusalem Post
DenovAI is approved by the Israel Innovation Authority and will receive a $2 million grant from AION Labs and its investment partners Pfizer, AstraZeneca, Merck, Teva and Israel Biotech Fund.
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
Word Pharma Today
BioMed X unveiled its new immunology discovery platform designed to allow for the accurate and fast identification of target antigens of human T cell receptors (TCRs).
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
Contract Pharma
The new technology functionally identifies and validates T cell target antigens, making it a powerful tool for immunology discovery.
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
Yahoo!
A new technology developed by BioMed X in collaboration with Janssen functionally identifies and validates T cell target antigens, making it a powerful tool for immunology discovery.
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
GlobeNewswire
The underlying technology emerged from a collaboration between BioMed X and Janssen Research & Development, LLC (Janssen). An international team of outstanding early-career researchers was recruited through the unique BioMed X crowdsourcing model. During a five-year research project at the BioMed X Institute in Heidelberg, the team developed a new platform technology for “Rapid Identification of Auto-Antigens in Autoimmune Diseases.”
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
FinanzNachrichten
BioMed X announced today the launch of its new immunology discovery platform that will allow for the accurate and fast identification of target antigens of human T cell receptors (TCRs). The research team led by John Lindner, who has developed the new technology, is based at the BioMed X Institute in Heidelberg, Germany.
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
BioSpace
A new technology developed by BioMed X in collaboration with Janssen functionally identifies and validates T cell target antigens, making it a powerful tool for immunology discovery.
Visit: Novel Alliance Responds to Big Pharma’s Most Pressing AI/ML Needs
Novel Alliance Responds to Big Pharma’s Most Pressing AI/ML Needs
BioSpace
Artificial intelligence and machine learning applications are not the future of drug development; they’re already here, being deployed at large pharmaceutical companies like Pfizer and Merck KGaA.
Visit: German research institute picks New Haven for first U.S. location
German research institute picks New Haven for first U.S. location
CT Insider
An independent research institute based in Germany has chosen New Haven as its first location here in the United States.
Visit: BioMed X to establish first US-based research institute in New Haven
BioMed X to establish first US-based research institute in New Haven
New Haven Biz
BioMed X, a biomedical research institute in Germany, is launching its first U.S. facility here in New Haven. The BioMed X Institute in New Haven will focus on research in the areas of immunology and tissue engineering.
Visit: German Biomed Researchers Pick New Haven For U.S. Post
German Biomed Researchers Pick New Haven For U.S. Post
New Haven Independent
A German biomedical research institute is putting down roots in New Haven, with newly announced plans to move into a local lab space later this year as it partners with a biopharmaceutical company to study immunology and tissue engineering. That research firm is called BioMed X.
Visit: BioMed X Extends Research Collaboration With AbbVie On Immunology And Tissue Engineering
BioMed X Extends Research Collaboration With AbbVie On Immunology And Tissue Engineering
RTT News/Nasdaq
BioMed X noted that the new US-based research collaboration will focus on immunology and tissue engineering, following a first joint research project on Alzheimer’s disease at the BioMed X Institute in Heidelberg, Germany.
Visit: BioMed X establishes its first US-based institute in New Haven with a new immunology research project in collaboration with AbbVie
BioMed X establishes its first US-based institute in New Haven with a new immunology research project in collaboration with AbbVie
BioSpace
“Extending our successful partnership with AbbVie to our new site in the US is a big milestone for our institute,” said Christian Tidona, Founder and Managing Director of BioMed X.
Visit: BioMed X and AbbVie Extend Research Collaboration in the US
BioMed X and AbbVie Extend Research Collaboration in the US
PharmiWeb
BioMed X establishes its first US-based institute in New Haven with a new immunology research project in collaboration with AbbVie.
Visit: BioMed X, AbbVie extend partnership to focus on immunology research
BioMed X, AbbVie extend partnership to focus on immunology research
Seeking Alpha
BioMed X is broadening an existing partnership with AbbVie to focus on immunology and tissue engineering. BioMed X is also launching a research institute in the US based in New Haven, CT.
Visit: BioMed X and AbbVie Extend Research Collaboration in the US
BioMed X and AbbVie Extend Research Collaboration in the US
CBS19 News
BioMed X establishes its first US-based institute in New Haven with a new immunology research project in collaboration with AbbVie.
Visit: BioMed X and AbbVie Extend Research Collaboration in the US
BioMed X and AbbVie Extend Research Collaboration in the US
Yahoo! Finance
BioMed X – an independent research institute – establishes its first US-based institute in New Haven, CT, with a new immunology & tissues engineering research project in collaboration with AbbVie.